Every 10-Q that Lineage Cell Therapeutics, Inc. (LCTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LCTX filings page.
Lineage Cell Therapeutics, Inc. reported Q1 2026 revenue of $1.7M, up from $1.5M a year earlier, driven mainly by collaboration income. Operating expenses rose to $9.3M, leading to a net loss attributable to Lineage of $4.8M, or $(0.02) per basic share.
Cash, cash equivalents and marketable securities totaled $53.4M as of March 31, 2026, and management believes this will fund planned operations for at least twelve months. The company continues to advance its OpRegen collaboration with Roche, OPC1 spinal cord program, and preclinical pipeline, while using an at-the-market facility and prior warrant financings for capital.
Lineage Cell Therapeutics reported Q3 2025 results. Total revenue was $3.68 million (collaboration revenue $3.54 million). Operating loss was $3.79 million as R&D of $3.27 million and G&A of $4.19 million outpaced revenue. A large non-cash expense from the change in fair value of warrant liability ($26.56 million) drove a GAAP net loss of $29.75 million for the quarter.
Cash, cash equivalents and marketable securities totaled $40.5 million at September 30, 2025, and management states this is sufficient for at least twelve months of planned operations. Deferred revenue declined to $16.23 million as performance obligations were recognized, and warrant liabilities rose to $45.17 million. During the quarter, the company raised $1.32 million via its ATM program. The pipeline advanced: OpRegen received FDA RMAT designation in 2024 and showed positive 36‑month data in June 2025; the OPC1 DOSED study dosed its first chronic SCI participant with no significant safety events through 60 days; and a WDI collaboration will fund up to $12 million in ReSonance preclinical work. Common shares outstanding were 230,327,537 as of October 31, 2025.
Lineage Cell Therapeutics reported stronger collaboration revenue and continued clinical progress while remaining a development-stage biotech with ongoing operating losses. Total revenues for the six months ended June 30, 2025 were $4.27 million, up from $2.85 million a year earlier, driven primarily by recognized collaboration upfront license fees. Cash and marketable securities totaled approximately $42.3 million at June 30, 2025 and management states these resources, together with available ATM capacity, are expected to fund planned operations for at least twelve months.
Operating results reflect continued R&D and G&A spending and a non-cash $14.84 million impairment of an acquired intangible asset, producing a net loss attributable to Lineage of $34.6 million for the six months. Balance sheet highlights include total assets of $90.8 million, warrant liabilities of $18.8 million (up from $6.2 million), and shareholders' equity of $47.1 million. Clinically, OpRegen showed sustained 36-month visual acuity gains in a subgroup (mean +9.0 ETDRS letters, n=5), OpRegen retains RMAT designation, and the OPC1 DOSED study has been initiated with the first chronic SCI patient treated.